FIELD: biotechnology.
SUBSTANCE: invention relates to proteins based on antibodies with a grafted cytokine to activate immune cells, and can be used in medicine to treat cancer. The following is proposed: a fusion protein design based on an antibody containing a heavy chain variable region (VH) and a light chain variable region (VL), in which a mutant interleukin 2 (IL2) molecule is grafted onto HCDR1.
EFFECT: invention provides for production of an immunocytokine with selectivity for activation of CD8+ T-cells with a decrease in the activation of Treg-cells, an increased half-life and effectiveness in the treatment of cancer.
29 cl, 8 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEINS BASED ON ANTIBODY WITH GRAFTED CYTOKINE AND METHODS FOR THEIR USE IN IMMUNE DISORDERS | 2018 |
|
RU2786730C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| DOSING REGIMEN OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN A COMBINATION | 2018 |
|
RU2767533C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIGENIC POLYPEPTIDES BASED ON OSPA SEQUENCE | 2019 |
|
RU2816208C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| NOVEL PROTEIN COMPOSITIONS OBTAINED BY RATIONAL DESIGN | 2019 |
|
RU2816719C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
